Developing effective immunotherapies for acute myeloid leukemia (AML) has long been hampered by a critical challenge: Therapy directed at killing the leukemia cells may also harm the body's ability to make new, healthy blood cells. This happens because most of the proteins that can be targeted on the surface of the blood cancer's cells are also found on vital blood-forming cells.